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Surges of Increased T Cell Reactivity to an Encephalitogenic
Region of Myelin Proteolipid Protein Occur More Often in
Patients with Multiple Sclerosis Than in Healthy Subjects1
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We have previously shown that patients with multiple sclerosis (MS) have increased T cell responses to the immunodominant
region (residues 184–209) of myelin proteolipid protein (PLP). The present study investigated whether this reactivity fluctuates
over time and correlates with disease activity. We performed monthly limiting dilution assays for 12–16 mo in four healthy
subjects and five patients with relapsing-remitting MS to quantify the frequencies of circulating T cells proliferating in response
to PLP41–58, PLP184–199, PLP190–209, myelin basic protein (MBP), MBP82–100, and tetanus toxoid. Disease activity was monitored
by clinical assessment and gadolinium-enhanced magnetic resonance imaging of the brain. There were fluctuations in the fre-
quencies of autoreactive T cells in all subjects. Compared with healthy controls, MS patients had significantly more frequent
surges of T cells reactive to the 184–209 region of PLP, but infrequent surges of T cell reactivity to MBP82–100. There was temporal
clustering of the surges of T cell reactivity to MBP82–100 and MBP, suggesting T cell activation by environmental stimuli. Some
clinical relapses were preceded by surges of T cell reactivity to PLP184–209, and in one patient there was significant correlation
between the frequency of T cells reactive to PLP184–199 and the total number of gadolinium-enhancing magnetic resonance
imaging lesions. However, other relapses were not associated with surges of T cell reactivity to the Ags tested. T cells reactive to
PLP184–209 may contribute to the development of some of the CNS lesions in MS. The Journal of Immunology, 2000, 165:
5322–5331.
T here is increasing evidence that multiple sclerosis (MS)3is an autoimmune disease (1, 2). In a large cross-sectionalstudy, we have previously shown that patients with re-
lapsing-remitting MS or secondary progressive MS have increased
peripheral blood T cell proliferative responses to two overlapping
peptides (residues 184–199 and 190–209) in the 184–209 region
of myelin proteolipid protein (PLP) (3). Epitopes within the same
region of PLP (residues 178–209) are encephalitogenic in a variety
of mice of different genetic backgrounds (4, 5). This region (res-
idues 180–199) is a dominant one recognized by human T cells
(control and MS) that have been stimulated several times in vitro
with PLP (6). A notable feature of peptides from the 184–209
region of PLP is that they are promiscuous in their binding to a
range of MHC class II molecules (5, 6). Indeed, this is why we
initially chose these PLP peptides for use in our MS research. In
our previous study, we also found that T cell lines stimulated with
whole PLP can recognize both PLP184–199 and PLP190–209 and that
T cell lines specific for these peptides can recognize the whole PLP
molecule (3). These results indicated that the intact PLP molecule
can be naturally processed into epitopes contained within the
PLP184–199 or PLP190–209 peptides.
The aims of the present study were to determine whether the
peripheral blood T cell response to the 184–209 region of PLP
changes over time in healthy subjects and patients with relapsing-
remitting MS and to determine whether changes in blood T cell
reactivity correlate with disease activity. Limiting dilution analysis
is a useful, reliable method to quantify T cell responses to Ags in
individual subjects over time (7, 8). We performed monthly lim-
iting dilution analysis to quantify the frequencies of circulating T
cells capable of proliferating in response to PLP41–58, PLP184–199,
PLP190–209, whole myelin basic protein (MBP), MBP82–100 (the
immunodominant region of MBP (9, 10)) and to a control Ag,
tetanus toxoid. Disease activity in the patients with MS was mon-
itored by monthly clinical assessment and by gadolinium-en-
hanced magnetic resonance imaging (MRI) of the brain.
Materials and Methods
Patients and healthy subjects
This study was approved by the Research Ethics Committee of the Royal
Brisbane Hospital and by the Medical Research Ethics Committee of the
University of Queensland. All subjects gave informed consent to partici-
pate in the study. The subjects of this study consisted of five patients with
clinically definite MS (11) of the relapsing-remitting type and four healthy
volunteers. The sex, age, duration of MS, and HLA haplotypes of the
subjects are shown in Table I. All subjects had been previously vaccinated
with tetanus toxoid, but none was vaccinated during the course of the study
or within 6 mo before commencement of the study. None of the patients
with MS was receiving any immunosuppressant, immunomodulatory, or
corticosteroid therapy at the time of commencement of the study, but three
were commenced on IFN-b-1b (8 3 106 U s.c. every second day) late in
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the study, and two received one course of i.v. methylprednisolone therapy
(500 mg daily for 5 days) for a relapse. Once a month, at the time of blood
collection, each patient with MS was assessed clinically by the same
investigator (R.D.H.). A clinical relapse was defined as an episode of
new or worsening neurological symptoms and new or worsening neuro-
logical signs without any other explanation (such as fever) and lasting for
at least 24 h.
HLA-DR and -DQ typing
Genomic DNA was prepared from whole blood or from EBV-transformed
lymphoblastoid cell lines from each subject. HLA-DR typing was per-
formed using Dynal (Dynal, Carlton South, Victoria, Australia) sequence-
specific primer sets according to the manufacturer’s instructions. HLA-DQ
typing was conducted at the Department of Immunology, Westmead Hos-
pital (Sydney, Australia). For HLA-DQ typing, DNA was initially ampli-
fied by PCR using generic primer pairs. HLA-DQA1 and -DQB1 alleles
were determined by RFLP analysis of the PCR products.
Antigens
PLP41–58 (GTEKLIETYFSKNYQDYE), PLP184–199 (QSIAFPSKTSA
SIGSL), and PLP190–209 (SKTSASIGSLCADARMYGVL) were synthe-
sized by Auspep (Melbourne, Australia) according to the human sequence
(12). They were .90% pure by HPLC analysis. PLP184–199 and PLP190–209
are moderately hydrophobic, and were dissolved at a concentration of 5
mg/ml in 0.2 M acetic acid before dilution in tissue culture medium for
limiting dilution assays. Human MBP was extracted from human brain
according to the method of Deibler et al. (13). MBP82–100 (DENPVVH
FFKNIVTPRTPP), numbered according to the human sequence, was syn-
thesized by Auspep. Tetanus toxoid was a gift from CSL (Melbourne,
FIGURE 1. Frequencies of circulating T cells capable of proliferating in response to specific Ags, as determined by monthly limiting dilution assays in
a healthy subject (DW).
Table I. Characteristics of healthy subjects and patients with MS
Subject Sex Agea Durationa of MS
HLA Haplotypes
DRB1 DQA1 DQB1
Healthy subjects
DW M 27 0701 0801 0201 0501 0201 0402
JP F 30 0101 1101
KC F 44 0301 0701 0201 0301 0201 0201
LA F 30 08 1501
Patients with MS
MS 6 F 57 14 1303 1501 0102 0501 0301 0602
MS 35 F 49 16 0701 1501 0102 0201 0201 0602/3
MS 42 F 38 13 1101 1501 0102 0501 0304 0602/3
MS 45 F 40 9 0401 1101 0301 0501 0301 0301
MS 48 F 47 10 0101 0401 0102 0301 0301 0501
a Age and duration of MS in years at the time of commencement of the study.
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Australia). PLP41–58, whole MBP, MBP82–100, and tetanus toxoid were
dissolved in water.
Limiting dilution assays
Heparinized blood was collected by venepuncture from each subject at
monthly intervals. PBMC were separated from the blood by centrifugation
through Histopaque (Sigma, St. Louis, MO) and washed twice. For the
limiting dilution assays, we used 96-well round-bottom microtiter plates
(Nunc, Roskilde, Denmark) containing 200 ml/well RPMl 1640 supple-
mented with 10% heat-inactivated pooled human serum, 2 mM L-glu-
tamine, and 10 mM HEPES buffer. The PBMC were added to the wells at
four different concentrations, 100,000, 50,000, 10,000, and 5,000 cells/
well. Twenty-four wells were prepared at each cell concentration for each
Ag. To each of the wells, 50,000 autologous irradiated PBMC were added
as APC. The Ags were added at the following concentrations: PLP41–58,
PLP184–199, PLP190–209 and MBP82–100 at 20 mg/ml; whole MBP at 30
mg/ml; and tetanus toxoid at 10 limes flocculation U (LF)/ml. The cultures
were incubated for 6 days, with 0.5 mCi [3H]thymidine being added during
the last 18 h. Cultures were harvested, and [3H]thymidine uptake was mea-
sured in cpm in a b-plate counter (LKB Instruments, Gaithersburg, MD).
Wells were considered positive if the cpm exceeded twice the mean cpm
for control wells (at the same concentration of responder PBMC) not con-
taining Ag and if it exceeded the control mean cpm 1 3 SD. The number
of negative wells for each Ag at each cell concentration was recorded and
used to determine the frequency of T cells capable of proliferating in re-
sponse to the specific Ag. To calculate the frequencies and the 95% con-
fidence intervals, we used a computer program written by Dr C. Schmidt
(Queensland Institute of Medical Research, Brisbane, Australia) that used
the maximum likelihood estimation method (14).
Magnetic resonance imaging
Four of the patients with MS had monthly MRI brain scans at the time of
blood collection. The scans were performed with a 1.5 T Siemens System
(Siemens, Erlangen, Germany). Scout images were taken to confirm the
similar positioning of all subjects, and axial scanning was conducted par-
allel to the plane defined by the anterior and posterior commissures on a
preliminary midline sagittal image. The slice thickness was 5 mm in the
first half of the study and 3 mm in the second half. T1-weighted imaging
was performed before and 5 min after the i.v. administration of dimeglu-
mine gadopentetate (gadolinium, 0.1 mmol/kg). All of the scans were as-
sessed by the same investigator (P.D.M.), who was unaware of the results
of the clinical assessment and the limiting dilution assays. This investigator
determined the total number of gadolinium-enhancing lesions $2 mm in
diameter and the number of new enhancing lesions since the previous scan.
Statistical analysis
The means of the T cell frequencies for each Ag in healthy subjects and
patients with MS were compared by Student’s t test after assessing for
differences between variances. A surge in T cell frequency was defined as
a frequency $2 SD above the mean frequency for that Ag in healthy
FIGURE 2. Profiles of the circu-
lating T cell frequencies over time
for each Ag in healthy subjects and
patients with MS. The bars in each
profile represent the 95% confidence
intervals of the T cell frequencies at
consecutive monthly time points; the
actual T cell frequency corresponds
to the dark point within each bar.
Dotted lines indicate the means 1 2
SD of the frequencies in healthy sub-
jects (see Table II).
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subjects. The percentages of time points at which surges occurred for each
Ag in healthy subjects and patients with MS were compared by the x2 test
with Yates’ correction. To determine whether the T cell frequencies cor-
related with the number of gadolinium-enhancing MRI lesions in individ-
ual patients, we used linear regression analysis.
Results
Findings in healthy subjects
The frequencies of peripheral blood T cells capable of proliferating
in response to the tested specific Ags measured at monthly inter-
vals are illustrated in detail for one of the healthy subjects in Fig.
1 and are summarized for all four healthy subjects in Fig. 2. It is
clear that in each healthy subject the T cell frequencies for at least
one myelin Ag fluctuated over time. From the total set of mea-
surements in the four healthy subjects, we calculated the mean and
SD of the T cell frequency for each Ag and defined a surge in the
T cell frequency as a frequency $2 SD above the mean (Table II).
Surges of high frequencies of T cells for each Ag occurred in at
least one of the healthy subjects and, in the case of MBP82–100, in
three of these subjects (Fig. 2 and Table III). The high frequencies
of T cells reactive to tetanus toxoid in two of the subjects (KC and
LA in Fig. 2) were not explained by recent vaccination.
Findings in patients with MS
The frequencies of peripheral blood T cells capable of proliferating
in response to the tested specific Ags measured at monthly inter-
vals are summarized for all five MS patients in Fig. 2 and are
illustrated in detail for each of the five patients in Fig. 3 and Figs.
5–8. Surges of high frequencies of T cells reactive to PLP190–209
occurred significantly more often in MS patients than in healthy
subjects (Fig. 2 and Table III). These surges occurred particularly
often in one MS patient (MS 48) (Figs. 2 and 5), but even when
this patient was excluded the surges occurred more often in the MS
patients than in the healthy subjects. Surges of high frequencies of
T cells reactive to the overlapping PLP184–199 peptide also oc-
curred more often in patients with MS but the difference was not
statistically significant. When the results for the two overlapping
PLP peptides were considered together, surges of high frequencies
of T cells reactive to the 184–209 region of PLP were found in
32.8% of the time points analyzed in the MS patients compared
with 12.0% of the time points in the healthy subjects ( p 5 0.016,
Table III). Surges of high frequencies of T cells reactive to
PLP184–199 and/or PLP190–209 occurred in all five patients with
MS (Fig. 2). The fluctuating nature of the T cell response is em-
phasized by the fact that the patient (MS 35) who, of these five
patients, had had the highest level of T cell reactivity to PLP190–
209 (stimulation index, 8.2) in our previously published cross-sec-
tional study (3) was the only patient who did not have one or more
surges of a high frequency of T cells reactive to this peptide in the
present longitudinal study (Figs. 2 and 6). Surges of high T cell
frequencies for MBP, but not MBP82–100, occurred more often in
patients with MS than in healthy subjects, but the difference was
not significant (Fig. 2 and Table III). The above differences be-
tween MS patients and healthy subjects were not altered by ex-
cluding the measurements made after the commencement of IFN-
b-1b late in the course of the study in three patients. The higher
and more variable T cell reactivity to the 184–209 region of PLP
in MS patients is also reflected in higher mean T cell frequencies
and variances for PLP184–199 and PLP190–209 (Table II).
Correlation with disease activity
In the patients with MS the frequencies of T cells reactive to
PLP184–199 or PLP190–209 partly correlated with disease activity as
assessed by clinical relapses or the number of gadolinium-enhanc-
ing lesions on MRI brain scans (Figs. 3–8). In patient MS 42, there
was a surge in the frequency of T cells reactive to PLP184–199 just
before the first relapse shown in Fig. 3; the T cell frequencies just
before the second relapse are unknown because blood was not
collected in the preceding month. High frequencies of T cells
Table II. T cell frequencies in healthy subjects and patients with MS
PLP41–58 PLP184–199 PLP190–209 MBP82–100 MBP Tetanus Toxoid
Healthy subjects
Meana 0.70 0.93 0.84 2.70 1.65 193
Variance 2.01 0.60 0.84 22.04 3.91 51,349
SD 1.42 0.78 0.91 4.69 1.98 227
Mean 1 2 SDb 3.53 2.48 2.67 12.09 5.61 646
Patients with MS
Mean 1.34 2.00 2.85 3.63 2.52 92
Variance 2.09 24.29 26.65 47.84 11.58 17,264
SD 1.45 4.93 5.16 6.92 3.40 131
F test ( p)c 0.887 ,0.001 ,0.001 0.005 ,0.001 ,0.001
t test ( p)d 0.019 0.084 0.003 0.390 0.085 0.006
a Frequency per 106 PBMC.
b Mean 1 2 SD in healthy subjects is the level defining a surge in frequency (see Materials and Methods).
c F test for equality of variances.
d t test for equality of means (assuming equal or unequal variances where appropriate).
Table III. Percentages of surges of T cell reactivity
PLP41–58 PLP184–199 PLP190–209
PLP184–199 or
PLP190–209 MBP82–100 MBP
Tetanus
Toxoid
Healthy subjects 2.0 8.0 4.2 12.0 8.0 4.0 16
Patients with MS 6.0 17.9 24.2 32.8 6.0 14.9 1.5
p a 0.500 0.201 0.008 0.016 0.500 0.102 0.010
a x 2 test on proportions.
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reactive to PLP184–199, PLP190–209, or MBP also preceded or oc-
curred concurrently with gadolinium-enhancing MRI brain lesions
(Fig. 3). Furthermore, there was a significant correlation between
the frequency of T cells reactive to PLP184–199 and the total num-
ber of gadolinium-enhancing MRI brain lesions in this patient (Fig.
4). In patient MS 48, a clinical relapse was preceded by a surge in
the frequency of T cells reactive to PLP190–209, although other
surges of this reactivity were not associated with relapses (Fig. 5).
Some of the surges in the frequencies of these T cells in this patient
were accompanied by increases in the frequencies of T cells reac-
tive to other Ags, including tetanus toxoid, particularly following
the i.v. administration of methylprednisolone for the relapse. This
posttreatment effect may represent a rebound phenomenon follow-
ing general immunosuppression by methylprednisolone. One of
the surges in the frequency of T cells reactive to PLP190–209
(March 1998, Fig. 5) was accompanied by the development of gad-
olinium-enhancing MRI brain lesions, but there was no significant
correlation between the number of gadolinium-enhancing MRI
brain lesions and the frequency of T cells reactive to PLP184–199 or
to PLP190–209 in this patient. Treatment with IFN-b-1b in patients
MS 42 and MS 48 suppressed the development of gadolinium-
enhancing MRI brain lesions (Figs. 3 and 5), as has been previ-
ously reported (15). This was associated with low frequencies of T
cells reactive to PLP184–199 or to PLP190–209 in patient MS 42 but
not in patient MS 48. In the other three MS patients, one relapse
was preceded by a surge in the frequency of T cells reactive to
FIGURE 3. Numbers of total and new gadolinium-enhancing MRI brain lesions, clinical relapse profile, and frequencies of circulating T cells capable
of proliferating in response to specific Ags, as determined by monthly limiting dilution assays, in patient MS 42. Bottom: F, total numbers of gadolinium-
enhancing lesions; E, numbers of new gadolinium-enhancing lesions. IFN-b, IFN-b-1b, 8 3 106 U s.c. every second day for the remainder of the study.
FIGURE 4. Correlation between the frequency of circulating T cells
capable of proliferating in response to PLP184–199, as determined by lim-
iting dilution analysis, and the total number of gadolinium-enhancing MRI
brain lesions at the same time points in a patient with MS (MS 42; also see
Fig. 3).
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PLP184–199 and to whole MBP (MS 35, Fig. 6), but three other
relapses were not preceded by an increase in T cell reactivity to
any of the Ags tested (Figs. 6 and 7). Two of these patients (MS
6 and MS 45) had no gadolinium-enhancing MRI brain lesions
throughout the study despite surges in the frequencies of T cells
reactive to the 184–209 region of PLP (Figs. 7 and 8). The other
patient (MS 35) did not undergo MRI scanning.
Temporal clustering of surges of high T cell reactivity to
myelin Ags
When the T cell frequencies of healthy subjects and MS patients
for each Ag were plotted against time, it became evident that there
was a temporal clustering of surges in the frequency of T cells
reactive to MBP82–100 in March–April 1998 (Fig. 9). During this
period, two healthy subjects and one patient with MS had a surge
in this reactivity, and in June 1998 a third healthy subject had such
a surge. This temporal clustering raises the possibility of the action
of an environmental factor such as infection by a virus or bacte-
rium. No symptoms of infection were detected in these subjects at
the time, but it is possible that these may have been missed. A
clustering of surges of reactivity to whole MBP was observed in
June–July 1997. During this time, three patients with MS had
surges in this reactivity (data not shown); blood was not collected
from the healthy subjects at these time points. There was no def-
inite temporal clustering of the surges in T cell reactivity to any of
the three PLP peptides.
Discussion
In this longitudinal study, we have shown that patients with re-
lapsing-remitting MS have recurrent surges of high frequencies of
circulating T cells capable of proliferating in response to the 184–
209 region of PLP. This region of PLP is encephalitogenic in mice
(4, 5) and immunodominant in humans (6). These surges occur
significantly more often than in healthy subjects and partly corre-
late with disease activity as assessed by clinical relapses and ga-
dolinium-enhancing MRI brain lesions. The mean frequencies of T
cells reacting to the 184–209 region of PLP were also higher in the
MS patients than in the healthy subjects, confirming the results of
our previously published cross-sectional study, which measured
stimulation indices in standard T cell proliferation assays (3). We
also found that surges of high T cell frequencies for the immuno-
dominant peptide of MBP, MBP82–100, occurred no more often in
FIGURE 5. Numbers of total and new gadolinium-enhancing MRI brain lesions, clinical relapse profile, and frequencies of circulating T cells capable
of proliferating in response to specific Ags, as determined by monthly limiting dilution assays, in patient MS 48. Bottom: F, total numbers of gadolinium-
enhancing lesions; E, numbers of new gadolinium-enhancing lesions. Mp 5 methylprednisolone 500 mg i.v. for 5 days; IFN-b, IFN-b-1b, 8 3 106 U s.c.
every second day for the remainder of the study.
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MS patients than in healthy subjects and that surges of high T cell
frequencies for whole MBP occurred more often, but the difference
was not significant. The mean frequencies of T cells reactive to
MBP82–100 or whole MBP in patients with MS were not signifi-
cantly different from those of healthy subjects, which is consistent
with the findings of our previous cross-sectional study (3), al-
though another cross-sectional study using limiting dilution anal-
ysis found a significantly higher frequency of T cells reactive to
whole MBP in eight MS patients compared with controls (16). As
the PLP and MBP peptides used in the present study bind with
high affinity to a broad range of HLA alleles (6, 17), we consider
that the differences we observed in T cell reactivity between the
MS patients and healthy subjects were not due to HLA differences.
It has been known for some time that healthy subjects possess T
cells capable of reacting to self Ags, but the present study has
revealed how the frequencies of circulating autoreactive T cells
fluctuate over time. We found that surges of high T cell reactivity
to all five myelin Ags tested occurred in healthy subjects. These
surges in the frequencies of circulating autoreactive T cells indi-
cate recent activation and expansion of these T cell populations.
The temporal clustering of the surges in the frequencies of T cells
reactive to MBP82–100 or MBP raises the possibility that these T
cells were activated through cross-reactivity (molecular mimicry)
after infection by a virus or bacterium. Recent evidence indicates
that T cells are much more cross-reactive than previously thought
(18) and that viral and bacterial peptides can activate myelin-re-
active human T cells (19, 20). Vandenbark et al. (21) have reported
temporal clustering of increases in T cell reactivity to whole MBP
in patients with MS. They did not find such increases in healthy
subjects but did not study the latter as often as the MS patients. It
would be expected that the activated myelin-reactive T cells would
enter the CNS in the healthy subjects, as activated T cells of any
specificity, including autoreactive T cells, enter the normal CNS
parenchyma (22, 23). The fate of myelin-reactive T cells in the
CNS in healthy subjects is unknown, but it has recently been sug-
gested that they may be eliminated by apoptosis (24), as occurs in
rats recovering from experimental autoimmune encephalomyelitis
(25, 26). We also observed some fluctuations in the frequencies of
T cells reactive to tetanus toxoid in healthy subjects. Some vari-
ation in the frequency of T cells reactive to tetanus toxoid in
healthy subjects over time has been previously observed (8) and
may reflect activation through cross-reactivity or general up-reg-
ulation of the immune system after infection.
Some of the surges in T cell reactivity to myelin Ags in patients
with MS may also be driven by cross-reactivity after viral or bac-
terial infection. Other surges may result from the activation of
autoreactive T cells after the release of myelin Ags from the CNS
during attacks of MS. Some previously activated myelin-reactive T
cells may be reactivated nonspecifically by a general up-regulation
of the immune system after infection. The latter mechanism may
account for those surges of high frequencies of myelin-reactive T
cells that occurred concurrently with high frequencies of T cells
reactive to tetanus toxoid in the present study. As in the case of
healthy subjects, it would be expected that the circulating activated
FIGURE 6. Clinical relapse profile and frequencies of circulating T cells capable of proliferating in response to specific Ags, as determined by monthly
limiting dilution assays, in patient MS 35. MP, Methylprednisolone 500 mg i.v. for 5 days.
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myelin-reactive T cells would enter the CNS in MS patients. It has
been hypothesized that, in contrast to the situation in healthy sub-
jects, these T cells may fail to undergo apoptosis in the CNS and
may thus be able to induce CNS demyelination with subsequent
release of myelin Ags (24). The released myelin Ags may reacti-
vate the originally aggressive autoreactive T cells and activate T
cells specific for other myelin Ags, leading to the perpetuation and
amplification of the autoimmune attack on the CNS.
In the present study, we found evidence that T cells reactive to
PLP184–209 may contribute to the pathogenesis of MS. Some of the
clinical relapses were preceded by surges in the frequency of cir-
culating T cells reactive to PLP184–209, and in one patient there
was a significant correlation between the frequency of circulating
T cells reactive to PLP184–199 and the total number of gadolinium-
enhancing MRI brain lesions. Gadolinium enhancement indicates
a breakdown of the blood-brain barrier and correlates with a
marked perivascular accumulation of inflammatory cells (27). It
often precedes other MRI abnormalities and clinical evidence of a
new lesion (28), although a recent study suggests that some lesions
may commence without a preceding phase of gadolinium enhance-
ment (29). We suggest that some of the gadolinium-enhancing
lesions and relapses in our patients developed as a consequence of
the entry of T cells reactive to PLP184–209 into the CNS following
an increase of these T cells in the circulation. However, some of
the surges of T cell reactivity to PLP184–209 were not associated
with either a clinical relapse or the development of gadolinium-
enhancing MRI brain lesions. The lack of a constant association
with clinical relapse is not surprising, given that clinical relapses
are insensitive indicators of disease activity compared with gado-
linium-enhanced MRI (30). Even with the use of gadolinium-en-
hanced brain MRI as in the present study, new lesions would have
been missed if they occurred in the spinal cord or optic nerve, if
they were small brain lesions, or if they developed without pre-
ceding gadolinium enhancement. Our study has also shown that
some clinical relapses are not associated with a surge in T cell
reactivity to PLP184–209, PLP41–58, MBP82–100, or whole MBP.
These relapses may have been induced by T cells reactive to other
myelin Ags, such as other epitopes of PLP, epitopes of myelin/
oligodendrocyte glycoprotein, or epitopes of the recently described
oligodendrocyte-specific protein (31) or myelin-associated oligo-
dendrocytic basic protein (32), but reactivity to these Ags was not
determined in the present study.
Given the abundance of MBP in the CNS it is noteworthy that
in contrast to the frequent surges of high T cell reactivity to
FIGURE 7. Numbers of total and new gadolinium-enhancing MRI brain lesions, clinical relapse profile, and frequencies of circulating T cells capable
of proliferating in response to specific Ags, as determined by monthly limiting dilution assays, in patient MS 6. Bottom: F, total numbers of gadolinium-
enhancing lesions; E, numbers of new gadolinium-enhancing lesions.
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PLP184–209, which contains the immunodominant PLP region,
surges of high T cell reactivity to the immunodominant MBP pep-
tide, MBP82–100, were infrequent in MS patients. There are several
possible explanations for this, including: more effective processing
of PLP epitopes than MBP epitopes from the native proteins re-
leased from CNS demyelinating lesions; higher binding of PLP
epitopes to MHC molecules and thus greater presentation to T
cells; higher levels of Abs to PLP epitopes with resultant greater
uptake of these epitopes by specific B cells and greater presenta-
tion by B cells to T cells; and apoptotic deletion of MBP-reactive
T cells, but not PLP-reactive T cells, in the peripheral nervous
system, which contains MBP but not PLP, although there may be
a failure of apoptosis of all autoreactive T cells in the CNS (24).
We have shown that the frequencies of circulating autoreactive
T cells fluctuate over time in both healthy subjects and patients
with MS. We also found that surges of high T cell reactivity to the
encephalitogenic 184–209 region of PLP occur more often in MS
FIGURE 8. Numbers of total and new gadolinium-enhancing MRI brain lesions, clinical relapse profile, and frequencies of circulating T cells capable
of proliferating in response to specific Ags, as determined by monthly limiting dilution assays, in patient MS 45. Bottom: F, total numbers of gadolinium-enhancing
lesions; E, numbers of new gadolinium-enhancing lesions. IFN-b, IFN-b-1b, 8 3 106 U s.c. every second day for the remainder of the study.
FIGURE 9. Scatter diagram of frequencies of circulating T cells capable
of proliferating in response to MBP82–100 at different time points in healthy
subjects and patients with MS. The dotted line indicates the mean 1 2 SD
of the frequencies in healthy subjects.
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patients than in healthy subjects. T cells reactive to this region of
PLP may contribute to the development of some of the demyeli-
nating lesions in the CNS in MS.
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